Jon Lim, FRCP PhD
@drjonlim.bsky.social
Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie • RISE Lead & MANIFEST Deputy Lead • ESMO #TranslationalResearch Faculty
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
Pinned
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
January 15, 2026 at 9:12 PM
🚀 Kicking off the new year with our next #ChristieFellowship session!
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
How do we communicate science well - to patients, the public, and on social media?
Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.
@christieinstitute.bsky.social
@mcrcnews.bsky.social
Reposted by Jon Lim, FRCP PhD
Thanks to @acir-org.bsky.social for highlighting our article!
January 14, 2026 at 5:43 PM
Thanks to @acir-org.bsky.social for highlighting our article!
Reposted by Jon Lim, FRCP PhD
❗Cross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology🤯
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
January 14, 2026 at 10:27 PM
❗Cross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology🤯
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk
Reposted by Jon Lim, FRCP PhD
NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'
Client Challenge
www.nature.com
January 14, 2026 at 8:40 AM
NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'
How does the immune system decide which tumour antigens remain visible over time❓
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
DC cross-presentation of dead cell F-actin antigens sculpts tumor evolution
Lim, Schulz, et al. studied the functioning of the F-actin receptor DNGR-1 on cDC1s, and the impact of cross-presentation on immunoediting of tumors using chemical carcinogenesis models. Dead cell-ass...
acir.org
January 14, 2026 at 2:53 PM
How does the immune system decide which tumour antigens remain visible over time❓
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.
Read further here 👇
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
January 13, 2026 at 5:46 PM
🤔 Do patients with cancer and clinicians see disease status the same way?
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.
Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...
🚨 NEW opportunity! 🚨
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
Translational Research Programme Manager :Paterson Building
As an equal opportunities employer we welcome applicants from all sections of the community regardless of age, sex, gender (or gender identity), ethnicity, disability, sexual orientation and transgender status. All appointments are made on merit.
www.jobs.manchester.ac.uk
January 12, 2026 at 5:49 PM
🚨 NEW opportunity! 🚨
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.
🗓️ Deadline: 30th January 2026.
🔗 To find out more and to apply:
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Cell therapy in sarcoma: current landscape and future directions
Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments,...
jitc.bmj.com
January 12, 2026 at 5:28 PM
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
@mcrcnews.bsky.social
@christieinstitute.bsky.social
It's the final week of our SCALE project, in partnership with @NationalCancerInstitute Ukraine and we are delighted to welcome to The Christie today, cohort three of our Ukrainian Observers. Follow their journey.
#cancercare #cancereducation #internationaleducation #internationalobservers #ukraine
#cancercare #cancereducation #internationaleducation #internationalobservers #ukraine
January 12, 2026 at 9:11 AM
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
@mcrcnews.bsky.social
@christieinstitute.bsky.social
Reposted by Jon Lim, FRCP PhD
Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
www.nature.com
January 6, 2026 at 12:51 PM
Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Jon Lim, FRCP PhD
Dendritic cells detect dead tumor cells using the DNGR-1 receptor, helping the immune system recognize and target cancer cells with specific mutations. This insight may inform future immunotherapies. doi.org/hbhtf6
Lifting cancer's invisibility cloak: Dying tumor cells alert the immune system
The immune system provides constant surveillance for the body, aiming to spot and eliminate disease-causing microbes or cancerous cells.
medicalxpress.com
January 5, 2026 at 3:18 PM
Dendritic cells detect dead tumor cells using the DNGR-1 receptor, helping the immune system recognize and target cancer cells with specific mutations. This insight may inform future immunotherapies. doi.org/hbhtf6
Reposted by Jon Lim, FRCP PhD
Thanks for highlighting our paper in your wonderful News & Views!
January 2, 2026 at 8:17 PM
Thanks for highlighting our paper in your wonderful News & Views!
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
January 4, 2026 at 10:25 PM
The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.
🔗 www.stem.org.uk/resources/li...
🔗 www.stem.org.uk/resources/li...
Reposted by Jon Lim, FRCP PhD
DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
January 2, 2026 at 8:52 PM
DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social
Reposted by Jon Lim, FRCP PhD
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
January 4, 2026 at 1:12 PM
Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure
Thanks for sharing @drjonlim.bsky.social & congrats 🥳
Reposted by Jon Lim, FRCP PhD
#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
doi.org
January 3, 2026 at 4:13 PM
#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!
Reposted by Jon Lim, FRCP PhD
@drjonlim.bsky.social & @reisesousalab.bsky.social show cDC1s & DNGR1 favor "tethered" neoantigens from F-actin proteins, trapping them in necrotic debris for better cross-presentation! Calls for prioritizing these neoantigens for cancer vaccine design #Immunotherapy www.nature.com/articles/s41...
Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology
Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...
www.nature.com
January 2, 2026 at 7:19 PM
@drjonlim.bsky.social & @reisesousalab.bsky.social show cDC1s & DNGR1 favor "tethered" neoantigens from F-actin proteins, trapping them in necrotic debris for better cross-presentation! Calls for prioritizing these neoantigens for cancer vaccine design #Immunotherapy www.nature.com/articles/s41...
Reposted by Jon Lim, FRCP PhD
Absolutely delighted that our latest paper is out today @natimmunol.nature.com. It has taken five years to uncover a role for cross-presentation in shaping the immune visibility of tumour antigens. A labour of love led by @drjonlim.bsky.social and Oliver Schulz. Great start of 2026!
Researchers at the Crick have uncovered how certain proteins that become exposed on dying tumour cells can be detected by the immune system, alerting it to the cancer’s presence and prompting an immune response.
www.crick.ac.uk/news/2025-12...
www.crick.ac.uk/news/2025-12...
Lifting cancer’s invisibility cloak
Dying tumour cells alert the immune system to fight cancer.
www.crick.ac.uk
January 2, 2026 at 5:26 PM
Absolutely delighted that our latest paper is out today @natimmunol.nature.com. It has taken five years to uncover a role for cross-presentation in shaping the immune visibility of tumour antigens. A labour of love led by @drjonlim.bsky.social and Oliver Schulz. Great start of 2026!
Very grateful to Prof. Blander & Dr. Jha for a thoughtful @natimmunol.nature.com 𝘕𝘦𝘸𝘴 & 𝘝𝘪𝘦𝘸𝘴 piece on our work 🙏
📄 A clear & critical perspective that places our findings in the broader context of dendritic cell biology, cross-presentation, and tumour immunoediting.
@reisesousalab.bsky.social
📄 A clear & critical perspective that places our findings in the broader context of dendritic cell biology, cross-presentation, and tumour immunoediting.
@reisesousalab.bsky.social
Tethered neoantigens from the dead sculpt tumor fate - Nature Immunology
New data show that DNGR-1 enables type 1 conventional dendritic cells to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens, enriching tumors for immune-e...
www.nature.com
January 2, 2026 at 5:22 PM
Very grateful to Prof. Blander & Dr. Jha for a thoughtful @natimmunol.nature.com 𝘕𝘦𝘸𝘴 & 𝘝𝘪𝘦𝘸𝘴 piece on our work 🙏
📄 A clear & critical perspective that places our findings in the broader context of dendritic cell biology, cross-presentation, and tumour immunoediting.
@reisesousalab.bsky.social
📄 A clear & critical perspective that places our findings in the broader context of dendritic cell biology, cross-presentation, and tumour immunoediting.
@reisesousalab.bsky.social
Reposted by Jon Lim, FRCP PhD
Researchers at the Crick have uncovered how certain proteins that become exposed on dying tumour cells can be detected by the immune system, alerting it to the cancer’s presence and prompting an immune response.
www.crick.ac.uk/news/2025-12...
www.crick.ac.uk/news/2025-12...
Lifting cancer’s invisibility cloak
Dying tumour cells alert the immune system to fight cancer.
www.crick.ac.uk
January 2, 2026 at 4:09 PM
Researchers at the Crick have uncovered how certain proteins that become exposed on dying tumour cells can be detected by the immune system, alerting it to the cancer’s presence and prompting an immune response.
www.crick.ac.uk/news/2025-12...
www.crick.ac.uk/news/2025-12...
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
January 2, 2026 at 4:57 PM
My main PhD paper is finally out! 🎉
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺.
@natimmunol.nature.com
It all started with an unexpected observation 🔍:
👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice.
1/11 🧵
🎙️ Great to hear Samra @turajliclab.bsky.social and @manifest-cirrp.bsky.social featured on BBC Radio 5 Live 👇
Samra Turajlić and @dremmacbw.bsky.social spoke to BBC Radio 5 Live about some of this year’s medical research advances, including their work on immunotherapy and Long COVID.
Listen from 53:10 and 2:46:00 ⤵️ www.bbc.co.uk/sounds/play/...
Listen from 53:10 and 2:46:00 ⤵️ www.bbc.co.uk/sounds/play/...
Sunday Breakfast - 28/12/2025 - BBC Sounds
Eleanor Oldroyd and Jeanette Kwakye presenting.
www.bbc.co.uk
December 29, 2025 at 6:41 PM
🎙️ Great to hear Samra @turajliclab.bsky.social and @manifest-cirrp.bsky.social featured on BBC Radio 5 Live 👇
Reposted by Jon Lim, FRCP PhD
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
December 29, 2025 at 1:01 PM
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🎙️ Enjoyed speaking with Salome Chkheidze, a medical student at Tbilisi State Medical University & journalist at Medscriptum, about precision oncology and the evolving opportunities (and challenges! of cell therapy in solid tumours.
Many thanks for the interview feature 👇
Many thanks for the interview feature 👇
Overcoming Barriers to Cell Therapy - From Spatial Immunology to the Scalability Gap - MedScriptum
In this interview, Dr. Lim unpacks the evolving role of cell therapies and reveals the gaps between promise and practice that call for fresh thinking.
medscriptum.org
December 27, 2025 at 2:41 PM
🎙️ Enjoyed speaking with Salome Chkheidze, a medical student at Tbilisi State Medical University & journalist at Medscriptum, about precision oncology and the evolving opportunities (and challenges! of cell therapy in solid tumours.
Many thanks for the interview feature 👇
Many thanks for the interview feature 👇